Table I.
Characteristics of participants.
| Variable | Prostate cancer | Benign prostatic hyperplasia | Healthy controls |
|---|---|---|---|
| Total subjects; n | 24 | 24 | 23 |
| Age, years; mean (range) | 71 (65–79) | 70 (66–78) | 71 (65–76) |
| Prostate-specific antigen, ng/ml; mean (± SD) | 17.8 (±4.72) | 10.5 (±2.65) | 3.5 (±0.40) |
| Gleason score; n (%) | |||
| <7 (low) | 5 (20.8) | – | – |
| 7 (intermediate) | 10 (41.7) | – | – |
| >7 (high) | 9 (37.5) | – | – |
| Tumor stage; n (%) | |||
| pT1/2 | 14 (58.3) | – | – |
| pT3/4 | 10 (41.7) | – | – |
| Node stage; n (%) | |||
| N0 | 22 (91.6) | – | – |
| N1 | 2 (8.3) | – | – |
| Metastasis stage; n (%) | |||
| M0 | 24 (100.0) | – | – |
| M1 | 0 (0.0) | – | – |